SK pharmteco und Prozomix geben strategische Zusammenarbeit bekannt, um die Biokatalyse-Kompetenzen für die weltweite Arzneimittelherstellung zu stärken

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Prozomix is very pleased to collaborate with a globally leading CDMO provider like SK pharmteco to ensure the full potential of their enzyme portfolio is realized in the most demanding pharmaceutical applications

  60% confidence

• Integrating Prozomix's enzyme diversity into SK pharmteco's global research, development, and production workflows complements existing technology platforms and enables the company to offer customers more innovative and sustainable solutions

  60% confidence

• Prozomix's ability to rapidly deploy large quantities of optimized enzymes, combined with SK pharmteco's outstanding manufacturing expertise, guarantees customers can transition from research phase to commercial production with unmatched speed and reliability

  60% confidence

• Prozomix has made a name globally by minimizing risks in the early phase of bioprocess development through its highly diverse enzyme panels and rapid scaling capabilities

  60% confidence

• As drug molecules become increasingly complex, the use of enzymes offers a more environmentally friendly, selective, and cost-effective alternative to traditional chemical synthesis

  60% confidence

• At SK pharmteco, our mission is to build close relationships with industry leaders based on trust, quality, and shared commitment to reliably deliver medicines to the highest standards

  60% confidence

Cited in these Via News reports

• Biotech Firms Secure Capital as Gene Therapy Trials Target 5 Million Global Patients with Dry AMD →